Trials comparing efficacy of melphalan prednisone (MP) with MP plus thalidomide in transplant ineligible, elderly patients with multiple myeloma have provided conflicting evidence. Although there is agreement regarding improved response rates (RRs) and higher toxicity with the addition of thalidomide to MP, the impact on progression free survival (PFS) and overall survival (OS) is less clear. We performed a meta-analysis comparing efficacy of melphalan, prednisone and thalidomide (MPT) and MP by pooling results on RR, PFS and OS reported in all the identified randomized controlled trials (RCTs) under a random effects model. Overall, six prospective RCTs, with data extractable from five published trials (n ¼ 1568) were identified. The pooled odds ratio of responding to therapy with MPT vs MP was 3.39 (Po0.001, 95% CI: 2.24-5.12). The pooled hazard ratios for PFS and OS were and 0.68 (Po0.001; 95% CI: 0.55-0.82) and 0.80 (P ¼ 0.07; 95% CI: 0.63-1.02), respectively, in favor of MPT. The odds ratios for high grade peripheral neuropathy and deep venous thrombosis were 6.6 and 2.4, respectively, in favour of MP. There was significant heterogeneity among the RCTs. Our meta-analysis demonstrates that in previously untreated, transplant ineligible, elderly myeloma patients, the addition of T to MP results in significantly improved RR and PFS with a trend towards improvement in OS compared with MP alone, but at a cost of significantly greater toxicity.
Introduction
The introduction of novel agents thalidomide, lenalidomide and bortezomib over the last decade has transformed the therapy for multiple myeloma (MM). Although a major focus of clinical investigation currently is to improve upon overall response rates (RRs) and eventually long-term control by assessing the efficacy of various front-line novel-agent combination regimens such as bortezomib, thalidomide, dexamethasone (VTD), bortezomib melphalan prednisone, thalidomide (VMPT) and bortezomib cyclophosphamide, lenalidomide and dexamethasone (VCRD), it is becoming increasingly clear that addition of an individual novel agent (thalidomide, lenalidomide or bortezomib) to traditional MP regimen could be synergistic and influence the disease outcome. Emergence of multiple active combination regimens has led to expansion of the management strategies.
Consequently, the appropriateness of the use and tolerability of such regimens in different patient populations is another area of active research interest among investigators.
Nearly two-thirds of patients with MM are older than 65 years of age. 1 Evidence from many single-institution experiences has suggested similar survival benefit for transplant eligible, elderly patients when compared with their younger counterparts. [2] [3] [4] However, in general, the options for the elderly are fewer, particularly for those with poor functional status and co-morbid illnesses who are unfit to undergo transplantation. In addition, chronological age of 65 years is used as cut-off for autologous stem cell transplantation (ASCT) in Europe. 5 Trials comparing efficacy of standard MP therapy with MP plus thalidomide in transplant ineligible or elderly patients with MM have provided conflicting evidence. [6] [7] [8] [9] [10] Although there is greater agreement with regard to superior RRs with the addition of thalidomide to MP in elderly/transplant ineligible patients, the impact on progression free survival (PFS) and overall survival (OS) is less clear with some trials demonstrating an improvement in PFS and/or OS with melphalan, prednisone and thalidomide (MPT) and others showing no difference in outcomes. [6] [7] [8] [9] [10] We performed a systematic review to integrate the existing outcome data related to the efficacy of MP vs MPT using a meta-analytic approach.
Methods
We used comprehensive strategies to identify potentially relevant randomized controlled trials (RCTs) through June 15th 2010. The published RCTs were searched through electronic databases (MEDLINE, EMBASE, Cancerlit) without language restrictions using the Cochrane collaboration optimal search strategy.
This was supplemented by manual searches of abstracts presented at the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and International Myeloma Foundation meetings in addition to the reference lists of the retrieved articles. We included only the prospective RCTs comparing MP with MPT in previously untreated elderly and/or transplant ineligible patients with MM that reported RR, progression-free or event-free survival (PFS/EFS), OS and treatment-related adverse effects on an intention-to-treat basis. The methodological quality of studies was rigorously assessed.
Data on RR, toxicity, specifically grade 3 or higher peripheral neuropathy (PN) and deep vein thrombosis (DVT), PFS and OS were pooled under a random effects model. 11 If relevant summary statistics were not readily available for the time-toevent data from the published articles, the methods described by Parmar et al. 12 were used. Specifically, information on observed number of events and reported P-value from the log-rank-test statistic was used to derive the point estimate and the variance of the log hazard ratio. The overall summary hazard ratios (HR) or odds ratios (OR) along with the corresponding 95% confidence intervals (CI) under a random effects model are reported.
The consistency of effects across studies was assessed using the Cochran's Q based on a w 2 statistic. However, given the small numbers of studies included in this meta-analysis, these statistics did not have sufficient power to detect true heterogeneity, and also did not adequately address whether the extent of heterogeneity impacts the final conclusions. Thus, heterogeneity was also assessed using I 2 , where values of I 2 from 0% to 25% denote low heterogeneity, from 25.1-50% indicate moderate heterogeneity, and greater than 50% indicate high heterogeneity. 13 The Begg and Egger funnel plot was used to assess publication bias. 14, 15 All statistical tests were twosided, and the analyses were performed using the Comprehensive Meta Analysis Software Version 2.2 (Biostat, Englewood, NJ, USA).
Results

Description of trials
Overall, six prospective RCTs comparing MP with MPT regimen were identified. [6] [7] [8] [9] [10] 16 Because of incomplete data reporting, we had excluded from our analysis, the Turkish trial (reported in abstract form) which had only commented upon the RRs and adverse events. 16 Data were extractable from the remaining five published RCTs for endpoints of ORR, OS and PFS. [6] [7] [8] [9] [10] 
Quality of the trials
All studies were RCTs with an adequate randomization procedure (Table 1) . Two trials had placebo-controlled designs wherein the study drug was blinded from the investigators, the patients and the monitors thereby, protecting against the biases observed in open-labeled studies. All the included trials have now been published. The Begg and Egger funnel plot for OS demonstrated a symmetric distribution (P ¼ 0.6) indicating no significant publication bias. Per initial design all the trials were appropriately powered for the respective primary endpoint. However, none of the trials went to full accrual and were stopped early because of the recommendations of the data safety monitoring boards or based on external evidence or slow accrual.
Overall response rates, progression-free survival and overall survival
The pooled HR for OS and PFS were 0.80 (P ¼ 0.07; 95% CI: 0.63-1.02, Figure 1 ) and 0.68 (Po0.001, 95% CI: 0.55-0.82, Figure 2 ), respectively, in favor of MPT. The pooled OR of responding to treatment with MPT vs MP was 3.39 (Po0.001, 95% CI: 2.24-5.12, Figure 3 ) indicating that MP was significantly less effective than MPT in achieving at least a partial response. Table 2 outlines the results of the sensitivity analysis for endpoints of OS and PFS. Significant heterogeneity persisted despite removal of GIMEMA or HOVON-49 studies. However, exclusion of the Nordic study from the analysis decreased the heterogeneity across studies (I 2 ¼ 42% and 40.2% for OS and PFS, respectively; P ¼ NS). In addition, removal of studies using maintenance T (GIMEMA, HOVON-49 and Nordic) or vice versa (IFM trials) resulted in marked reduction in heterogeneity ( Table 2) .
Toxicity
Discussion
Melphalan has been the mainstay of therapy of MM patients for more than half a century. Prednisone as a single agent has also been shown to produce an objective response rate of 44% in a reanalysis of two myeloma treatment protocols. 17 The classic MP combination was born in 1969 when a trial of 183 patients with melphalan versus MP demonstrated a survival improvement by 6 months in MP arm. 18 Over the next 3 decades, multiple combination chemotherapies were compared with MP, yielding conflicting results. A meta-analysis of 18 trials suggested no difference in therapeutic efficacy. 19 The debate on greater efficacy of these aggressive combination regimens was eventually put to rest in 1998 when an individual pooled data overview of 4930 patients from twenty RCTs (with the addition of published data on another 1703 patients from seven trials) demonstrated no significant difference in OS with combination chemotherapies over MP despite significantly higher RRs (60 v 53.2%; Po0.00001). 20 Thus, the less toxic MP regimen remained the standard of care.
Myeloablative doses of melphalan with stem-cell rescue further improved median OS, and consequently became the most acceptable management strategy for transplant eligible patients. 5, 21, 22 In 1990s, a landmark trial demonstrated an objective response of 32% with thalidomide in relapsed and refractory MM. 23 In combination with dexamethasone (D), the RRs increased to 41-65%. [24] [25] [26] In the front-line setting, TD showed a higher RR (63 vs 41% for D, P ¼ 0.001) and time to progression at the cost of substantially higher grades 3 and 4 DVT (17 vs 3%) and PN (7 vs 4%). 27 Typically, combination regimens can be justified when mechanisms for synergy are clearly defined. Despite highly potent in vivo effects, the preclinical activity of thalidomide in MM is modest, and synergy of thalidomide, which requires conversion to an active metabolite, with melphalan, is difficult to ascertain in vitro. Clinically, however, Offidani et al. 28 demonstrated greater activity of oral TM regimen over thalidomide alone (2-year PFS, 61 vs 45% with P ¼ 0.037) but OS difference was not noted.
In elderly patients and those who are transplant ineligible for reasons besides chronological age, the therapeutic approaches Therapy in transplant ineligible myeloma: a meta-analysis P Kapoor et al In 2002, a single UK Myeloma Forum Study involving 22 transplants ineligible patients (13 untreated, 9 previously treated) attempted to assess the safety and efficacy of MPT in patients. Although a 41% PR rate was noted, the study was closed prematurely because of the high incidence (3/13) of venous thromboembolism. 30 In the newly diagnosed MM patients, six phase III trials comparing MPT with MP have been conducted to date following promising results of a phase II study by Palumbo et al. 31, 32 However, somewhat conflicting conclusions of these trials has made the interpretation difficult. Although disparate outcomes could be attributed to different study designs and patient populations in these trials, our meta-analysis attempted to answer the critically pertinent question of benefit, or lack thereof, of adding thalidomide to the conventional MP regimen.
Interestingly, all trials were conducted in the European Union where patients of 65 years or older are generally not offered ASCT. The quest for effective therapeutic approaches in this cohort of patients is important because the median age of MM patients at diagnosis is B70 years.
A closer look at the studies included in our analysis identifies distinctive features of each one that could possibly have As melphalan was given until plateau. Therapy in transplant ineligible myeloma: a meta-analysis P Kapoor et al influenced outcomes (Table 1 ). As systematic reviews analyze studies that are diverse both clinically and methodologically, heterogeneity in the outcomes is not unexpected. In our meta-analysis heterogeneity has likely arisen as a consequence of differences in the definitions of outcome measures, duration of follow-up, drug dosages and inclusion criteria. In addition, maintenance therapy was used in only three out of the five studies. Although in the GIMEMA trial, PFS and OS were calculated from the time of diagnosis, these end-points were calculated from the time of random assignment or registration for the others. 8 Outcomes based on adequate genetic risk stratification, which has substantial prognostic implications, were mostly unavailable in these trials. While the HOVON-49 and IFM-01-01 studies focused exclusively on patients greater than 65 years and 75 years of age, respectively, IFM 99-06 enrolled patients between 65-75 years or less than 65 years, if transplant ineligible. 6, 7, 10 The other two trials permitted enrollment of any transplant ineligible patient irrespective of age. 8, 9 The exclusive enrollment of patients above 75 years of age in IFM 01-01 trial is noteworthy as it focused on the often excluded, but sizable proportion (B20%) of myeloma patients. 7 The Nordic study cohort was remarkable for involvement of 30% patients with poor performance status (ECOG 3 and 4), a sub-group that is mostly inadequately represented in clinical trials performed currently. 9 Importantly, the dose intensities of all three drugs (M, P and T) differed amongst the five trials. Melphalan and thalidomide doses were lowest in IFM 01-01 study (involving patients above 75 years of age), yet it demonstrated survival advantage of MPT arm. 7 Although evaluation of optimal dose of thalidomide was not the objective of any of the trials, the Nordic group made an important indirect inference from their study that better tolerated lower doses of thalidomide (100-200 mg) were sufficient and comparable to higher doses of thalidomide at 400 mg used in their induction phase and 200 mg in the maintenance phase. 9 With such high doses, better RRs did not translate into survival benefit in the MPT arm. 9 Moreover, nearly a third of patients had discontinued treatment by 3 months, and cessation of therapy increased to 56% by end of first year. Furthermore, during the first 6 months of treatment, the Nordic study reported 35 deaths in the MPT arm, 23 among patients older than 75 years of age. 9 Importantly, the three non-French trial designs [8] [9] [10] included maintenance therapy with thalidomide in the MPT arm, further complicating cross-trial comparisons with the two IFM studies. 6, 7 The IFM 99-06 also included a third arm of VAD induction followed by melphalan at 100 mg/m 2 with stem-cell rescue. RRs of VGPR or greater in MPT arms were comparable (47 vs 45%) between IFM 96-06 and the Italian study, with similar PFS (27.5 months vs 21.8 months). 6, 8 Yet the longer PFS of MPT arm in the Italian study did not result in substantially improved OS. On relapse or progression, 41% of patients in the MP arm in this study crossed over to receive bortezomib or thalidomide-based regimes, which probably accounts for lack of survival advantage with upfront MPT. 8 Similarly, in the Nordic study OS was comparable between the two arms, despite protracted maintenance therapy with high doses (200 mg/day) of thalidomide, and attainment of longer PFS in patients receiving MPT. 9 A sensitivity analysis was performed to detect studies leading to significant heterogeneity in our analysis. The two French trials with straightforward designs of random assignments to MP or MPT, without thalidomide maintenance, demonstrated superior outcome in all survival endpoints in the MPT arm. Exclusion of studies with T maintenance therapy resulted in complete disappearance of heterogeneity for OS. When the Nordic study was excluded from the analysis, the heterogeneity across trials became insignificant for both PFS and OS outcomes ( Table 2) .
Concurrent administration of myelosuppressive drugs has the potential to enhance the adverse effects and requires dose reduction as compared with monotherapy. Although a higher incidence of grade 3 or 4 neutropenia was observed in the MPT arms of both the IFM studies, no differences in severe infections were noted compared to MP. In contrast, the GIMEMA study demonstrated more frequent severe infections in the MPT arm despite lack of any observable difference in the rates of neutropenia between the two groups.
Venous thromboembolism is a known adverse effect of thalidomide. None of the trials used deep venous thrombosis (DVT) prophylaxis initially. Only GIMEMA and HOVON-49 study protocols were subsequently revised to include prophylaxis against this complication.
8, 10 The rates of thromboembolism were reduced from 20 to 3% with adequate DVT prophylaxis in GIMEMA study. 8 Although routine prophylaxis was not recommended in the Nordic study, the low incidence of DVT in the two arms may be explained by the use of drugs with anti-thrombotic effect in up to 40% of patients. 9 We now know that the risk of venous thromboembolism can be reduced by adhering to the current recommendations for the prevention of IMiD-induced DVT. 33 The incidence of PN increases with prolonged use of thalidomide due to cumulative neurotoxicity. More than 50% of patients treated for a year suffered from PN, although in most Therapy in transplant ineligible myeloma: a meta-analysis P Kapoor et al patients enrolled in these studies it was of low grade (p2). Treatments of shorter duration at lowest effective doses could decrease its incidence. In addition, physicians and patients should remain alerted, and promptly reduce/discontinue thalidomide upon development of painful paresthesias, onset of motor dysfunction, or interference with daily activities. Appropriate and timely prophylactic and therapeutic interventions can make these adverse effects manageable.
This meta-analysis successfully distills the discordant results of incorporated trials, taking into account the heterogeneity across the studies. Undoubtedly, despite substantial heterogeneity across studies, the overall RRs were overwhelmingly superior with addition of thalidomide (with or without maintenance) to MP, translating into significantly longer overall PFS and nearly significant OS benefit in our analysis. The grades 3 and 4 toxicities of DVT and PN, as expected, were substantially higher with the three-drug regimen.
Over the last few years, regimens incorporating the combination of MP with novel agents have improved the treatment of transplant ineligible patients. The ORR and PFS with MPT-based trials are comparable to those seen in the VISTA trial involving VMP (ORR ¼ 71%, PFS ¼ B24 months), an effective, alternative Therapy in transplant ineligible myeloma: a meta-analysis P Kapoor et al regimen for the elderly, transplant ineligible patients. 34 MPR is another effective regimen, and an ongoing ECOG trial is comparing MPR with MPT regimen. 35 Recently, a three-drug regimen, ThaDD (thalidomide, pegylated liposomal doxorubicin and intermediate dose dexamethasone) has demonstrated significantly higher overall response (87.5 vs 61.5%) compared with MPT in patients over 75 years, without any significant improvement in PFS and OS. 36 Another phase III, multicenter, randomized trial comparing efficacy and safety of lenalidomide plus low-dose dexamethasone (Rd) with MPT is currently underway (http://www.cancer.gov/search/ResultsClinicalTrials. aspx?protocolsearchid ¼ 7963791).
Reassuringly, the results of our meta-analysis seem to be similar to the recently presented abstract of individual pooled data analysis of six RCTs (PFS, HR ¼ 0.67 (CI: 0.55-0.80); OS, HR ¼ 0.82, (CI: 0.66-1.02)), which included the patients enrolled by the Turkish Myeloma Study Group. 37 This individual patient data analysis of 1682 subjects confirmed a significant impact on PFS and a nearly significant difference in the OS with addition of T to MP. 37 Our robust outcome data allow us to state with reasonable confidence that this three-drug regimen seems to have superior outcome, albeit at a cost of greater toxicity. Although it is our overriding recommendation that whenever feasible, elderly patients be enrolled in clinical trials, outside of a clinical trial setting, if MPT is considered, the doses have to be carefully adjusted. In particular, increasing the dose of thalidomide in the very elderly population can be associated with adverse outcomes as demonstrated by the Nordic trial. As such, one proposal in the absence of well-defined, optimal dosage of thalidomide, and more in line with the IFM 99-06 and IFM 01-01 regimens, is outlined in Table 3 . In conclusion, MPT can be considered one of the new standards of care for elderly and/or transplant ineligible MM patients. Randomized trials comparing other new combination regimens with MPT would further advance the field for such patients who comprise a sizable proportion of the myeloma patient-population. Dose of thalidomide should be promptly reduced by 50% with Grade 1 to Grade II peripheral neuropathy or intolerance. In the absence of data, for patients X75 years of age some experts suggest using melphalan at 0.13-0.18 mg/kg and thalidomide at 50 mg daily or every other day.
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